datasource: 2018.01.17
description: Flags validated oncogenic alterations and genomic biomarkers of drug response, while predicting cancer drivers among mutations of unknown significance.
developer:
  name: 'Global Alliance for Genomics and Health'
  organization: 'Global Alliance for Genomics and Health'
  email: 'support@cravat.us'
  website: 'https://www.cancergenomeinterpreter.org/biomarkers'
  citation: 'Tamborero, David, et al. "Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations." Genome medicine 10.1 (2018): 25.'

level: variant

output_columns:
- name: association
  title: Association
  type: string
  width: 80
  hidden: false
  category: single
  desc: How the presence of the biomarker affects the response to the drug.

- name: biomarker
  title: Biomarker
  type: string
  width: 80
  hidden: true
  desc: Genetic alteration described as a biomarker of response to a drug.

- name: drug
  title: Drug
  type: string
  width: 80
  hidden: true
  desc: Drugs influenced by the biomarker.

- name: evidence
  title: Evidence
  type: string
  width: 100
  hidden: true
  desc: The level of evidence that supports the described biomarker.

- name: source
  title: Source
  type: string
  width: 100
  hidden: true
  desc: Reference supporting the biomarker.

- name: tumor
  title: Tumor Type
  type: string
  width: 160
  hidden: false
  desc: The tumor type in which the biomarker has been described. 

tags:
- cancer
- clinical relevance

commercial_warning: 'Freely available for non-commercial use.'

title: Cancer Genome Interpreter
version: 1.0.0
type: annotator





